11:14 AM EDT, 05/30/2024 (MT Newswires) -- Biomea Fusion ( BMEA ) said Thursday it completed enrollment of the first three dose expansion arms of a phase 1/2 trial of BMF-219, with more than 260 people with type 2 diabetes enrolled.

The first three arms of the trial's dose escalation phase are assessing BMF-219 over eight and 12 weeks at 100 milligrams and 200 milligrams with up to 40 weeks of follow-up off treatment, the company said.

Topline data from this phase are expected to be presented in Q4, the company added.

Price: 11.01, Change: +0.12, Percent Change: +1.10